Additionally, IL-6 treatment of normal fibroblasts increased paxillin alignment, while tocilizumab treatment of keloid fibroblasts decreased paxillin alignment, showing that this response was downstream of IL-6 signaling (Fig. 8E–H). Here, PXN is linked to keloid.